Abstract
The goals of treatment for ulcerative colitis (UC) are to induce and maintain corticosteroid-free remission, thereby reducing hospitalizations and surgeries and preventing longer-term disease complications including colorectal cancer. Despite an incomplete evidence base, thiopurine immunomodulators remain a principle therapeutic option for patients failing aminosalicylate monotherapy and requiring multiple courses of corticosteroids. In this review, we outline the current evidence supporting the role of thiopurines in achieving these treatment goals in UC, including discussions of the important safety issues regarding their use. We also explore some of the recent evidence emerging in regards to the risks of lymphoproliferative disease, dosage optimization strategies and the role of thiopurines in achieving mucosal healing in UC and ultimately changing natural history outcomes for our patients.
Keywords: Azathioporine, 6-mercaptopurine, thiopurines, immunomodulators, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Colonoscopy, AZA, Nodular regenerative hyperplasia
Current Drug Targets
Title: Thiopurine Immunomodulators in Ulcerative Colitis: Moving Forward with Current Evidence
Volume: 12 Issue: 10
Author(s): Richard J. La Nauze and Miles P. Sparrow
Affiliation:
Keywords: Azathioporine, 6-mercaptopurine, thiopurines, immunomodulators, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Colonoscopy, AZA, Nodular regenerative hyperplasia
Abstract: The goals of treatment for ulcerative colitis (UC) are to induce and maintain corticosteroid-free remission, thereby reducing hospitalizations and surgeries and preventing longer-term disease complications including colorectal cancer. Despite an incomplete evidence base, thiopurine immunomodulators remain a principle therapeutic option for patients failing aminosalicylate monotherapy and requiring multiple courses of corticosteroids. In this review, we outline the current evidence supporting the role of thiopurines in achieving these treatment goals in UC, including discussions of the important safety issues regarding their use. We also explore some of the recent evidence emerging in regards to the risks of lymphoproliferative disease, dosage optimization strategies and the role of thiopurines in achieving mucosal healing in UC and ultimately changing natural history outcomes for our patients.
Export Options
About this article
Cite this article as:
J. La Nauze Richard and P. Sparrow Miles, Thiopurine Immunomodulators in Ulcerative Colitis: Moving Forward with Current Evidence, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818180
DOI https://dx.doi.org/10.2174/138945011796818180 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Impact on DNA Methylation in Cancer Prevention and Therapy by Bioactive Dietary Components
Current Medicinal Chemistry Comparative DFT Study of 5-Fluorouracil Adsorption on Silica and Graphene for Bio-Medical Applications
Micro and Nanosystems Patent Selections
Recent Patents on DNA & Gene Sequences Definition of Markov-Harary Invariants and Review of Classic Topological Indices and Databases in Biology, Parasitology, Technology,and Social-Legal Networks
Current Bioinformatics MicroRNA Regulatory Network in Human Colorectal Cancer
Mini-Reviews in Medicinal Chemistry MicroRNA-183 Functions As an Oncogene by Regulating PDCD4 in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Electroporation Advances in Large Animals
Current Gene Therapy Sera/Organ Lysates of Selected Animals Living in Polluted Environments Exhibit Cytotoxicity against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanism Behind the Synergistic Activity of Diphenylmethyl Selenocyanate and Cisplatin Against Murine Tumor Model
Anti-Cancer Agents in Medicinal Chemistry Cell Cycle Regulation in the G1 Phase: A Promising Target for the Development of New Chemotherapeutic Anticancer Agents
Current Medicinal Chemistry Intervening Stemness and Angiogenesis in Cervical Carcinoma: Revisiting the Efficacy of Natural Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Precise Analysis of the Autofluorescence Characteristics of Rat Colon Under UVA and Violet Light Excitation
Current Pharmaceutical Biotechnology Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment
Current Pharmaceutical Design Pharmacokinetics of 3’-O-Retinoyl-5-fluoro-2’-deoxyuridine (RFUdR), a Dual Acting Mutually Masking Prodrug, and Its Metabolites in Tumor Bearing Mice
Current Drug Delivery Health Outcomes Associated with Hormone Therapy in Australian Women
Current Drug Safety Nutraceuticals for Protection and Healing of Gastrointestinal Mucosa
Current Medicinal Chemistry Chemopreventive Effects of Conjugated Linolenic Acids (CLN) Occurring in Plant Seed Oils
Current Nutrition & Food Science Aging as an Epigenetic Phenomenon
Current Genomics In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine